424 related articles for article (PubMed ID: 12172555)
1. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.
Gao X; Zhang Y; Arrazola P; Hino O; Kobayashi T; Yeung RS; Ru B; Pan D
Nat Cell Biol; 2002 Sep; 4(9):699-704. PubMed ID: 12172555
[TBL] [Abstract][Full Text] [Related]
2. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
3. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila.
Stocker H; Radimerski T; Schindelholz B; Wittwer F; Belawat P; Daram P; Breuer S; Thomas G; Hafen E
Nat Cell Biol; 2003 Jun; 5(6):559-65. PubMed ID: 12766775
[TBL] [Abstract][Full Text] [Related]
4. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.
Zhang Y; Gao X; Saucedo LJ; Ru B; Edgar BA; Pan D
Nat Cell Biol; 2003 Jun; 5(6):578-81. PubMed ID: 12771962
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
6. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase.
Avruch J; Hara K; Lin Y; Liu M; Long X; Ortiz-Vega S; Yonezawa K
Oncogene; 2006 Oct; 25(48):6361-72. PubMed ID: 17041622
[TBL] [Abstract][Full Text] [Related]
7. Rheb promotes cell growth as a component of the insulin/TOR signalling network.
Saucedo LJ; Gao X; Chiarelli DA; Li L; Pan D; Edgar BA
Nat Cell Biol; 2003 Jun; 5(6):566-71. PubMed ID: 12766776
[TBL] [Abstract][Full Text] [Related]
8. The TOR nutrient signalling pathway phosphorylates NPR1 and inhibits turnover of the tryptophan permease.
Schmidt A; Beck T; Koller A; Kunz J; Hall MN
EMBO J; 1998 Dec; 17(23):6924-31. PubMed ID: 9843498
[TBL] [Abstract][Full Text] [Related]
9. TSC1/2 tumour suppressor complex maintains Drosophila germline stem cells by preventing differentiation.
Sun P; Quan Z; Zhang B; Wu T; Xi R
Development; 2010 Aug; 137(15):2461-9. PubMed ID: 20573703
[TBL] [Abstract][Full Text] [Related]
10. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.
Fingar DC; Blenis J
Oncogene; 2004 Apr; 23(18):3151-71. PubMed ID: 15094765
[TBL] [Abstract][Full Text] [Related]
11. L-leucine availability regulates phosphatidylinositol 3-kinase, p70 S6 kinase and glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the involvement of the mammalian target of rapamycin (mTOR) pathway in the L-leucine-induced up-regulation of system A amino acid transport.
Peyrollier K; Hajduch E; Blair AS; Hyde R; Hundal HS
Biochem J; 2000 Sep; 350 Pt 2(Pt 2):361-8. PubMed ID: 10947949
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation and binding partner analysis of the TSC1-TSC2 complex.
Nellist M; Burgers PC; van den Ouweland AM; Halley DJ; Luider TM
Biochem Biophys Res Commun; 2005 Aug; 333(3):818-26. PubMed ID: 15963462
[TBL] [Abstract][Full Text] [Related]
13. Opposite effects of tor1 and tor2 on nitrogen starvation responses in fission yeast.
Weisman R; Roitburg I; Schonbrun M; Harari R; Kupiec M
Genetics; 2007 Mar; 175(3):1153-62. PubMed ID: 17179073
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
[TBL] [Abstract][Full Text] [Related]
15. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.
El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ
Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP
Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026
[TBL] [Abstract][Full Text] [Related]
17. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.
Uhlmann EJ; Apicelli AJ; Baldwin RL; Burke SP; Bajenaru ML; Onda H; Kwiatkowski D; Gutmann DH
Oncogene; 2002 Jun; 21(25):4050-9. PubMed ID: 12037687
[TBL] [Abstract][Full Text] [Related]
18. Rheb activation of mTOR and S6K1 signaling.
Hanrahan J; Blenis J
Methods Enzymol; 2006; 407():542-55. PubMed ID: 16757352
[TBL] [Abstract][Full Text] [Related]
19. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.
Inoki K; Li Y; Zhu T; Wu J; Guan KL
Nat Cell Biol; 2002 Sep; 4(9):648-57. PubMed ID: 12172553
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]